Related references
Note: Only part of the references are listed.Involvement of UDP-Glucuronosyltransferases UGT1A9 and UGT2B7 in Ethanol Glucuronidation, and Interactions with Common Drugs of Abuse
Alaa Al Saabi et al.
DRUG METABOLISM AND DISPOSITION (2013)
The Medicinal Use of Cannabis and Cannabinoids-An International Cross-Sectional Survey on Administration Forms
Arno Hazekamp et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2013)
Comparison in the In Vitro Inhibitory Effects of Major Phytocannabinoids and Polycyclic Aromatic Hydrocarbons Contained in Marijuana Smoke on Cytochrome P450 2C9 Activity
Satoshi Yamaori et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands
Krishna C. Chimalakonda et al.
DRUG METABOLISM AND DISPOSITION (2012)
Conjugation of Synthetic Cannabinoids JWH-018 and JWH-073, Metabolites by Human UDP-Glucuronosyltransferases
Krishna C. Chimalakonda et al.
DRUG METABOLISM AND DISPOSITION (2011)
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Satoshi Yamaori et al.
DRUG METABOLISM AND DISPOSITION (2011)
Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids
Satoshi Yamaori et al.
FORENSIC TOXICOLOGY (2011)
Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes
Rongrong Jiang et al.
LIFE SCIENCES (2011)
Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety
Satoshi Yamaori et al.
LIFE SCIENCES (2011)
Beyond THC: the new generation of cannabinoid designer drugs
Liana Fattore et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2011)
Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes
Satoshi Yamaori et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)
Nicolas Tournier et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Potency Trends of Δ9-THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008
Zlatko Mehmedic et al.
JOURNAL OF FORENSIC SCIENCES (2010)
Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds
Sebastian Dresen et al.
JOURNAL OF MASS SPECTROMETRY (2010)
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2
R. G. Pertwee et al.
PHARMACOLOGICAL REVIEWS (2010)
Interindividual Variation in the Pharmacokinetics of Δ9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9
C. Sachse-Seeboth et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
Anna Mazur et al.
DRUG METABOLISM AND DISPOSITION (2009)
Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1)
Michelle L. Holland et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids
M. L. Holland et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Comparing test searches in PubMed and google scholar
Mary Shultz
JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION (2007)
Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes
Kazuhito Watanabe et al.
LIFE SCIENCES (2007)
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel
Frederike K. Engels et al.
ONCOLOGIST (2007)
Human cannabinoid pharmacokinetics
Marilyn A. Huestis
CHEMISTRY & BIODIVERSITY (2007)
Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana
HJ Zhu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Cannabinoids in medicine: A review of their therapeutic potential
MB Amar
JOURNAL OF ETHNOPHARMACOLOGY (2006)
The endocannabinoid system as an emerging target of pharmacotherapy
Pal Pacher et al.
PHARMACOLOGICAL REVIEWS (2006)
Chemical constituents of marijuana: The complex mixture of natural cannabinoids
MA ElSohly et al.
LIFE SCIENCES (2005)
Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract
T Nadulski et al.
THERAPEUTIC DRUG MONITORING (2005)
CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin
TM Bland et al.
BIOCHEMICAL PHARMACOLOGY (2005)
The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir
BW Kosel et al.
AIDS (2002)
Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and Δ9-tetrahydrocannabinol
MD Roth et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2001)
Pharmacology and effects of cannabis: a brief review
CH Ashton
BRITISH JOURNAL OF PSYCHIATRY (2001)